31,32 The main advantage of rituximab is sustained platelet responses that last more than 2 years in 50% of patients who have a response. 40,41 Although ITP eventually relapses in most patients ...

In addition to their reported side effects, some patients with ITP stop responding or have insufficient response to these therapies. More than ten years ago, researchers identified rituximab as an ...

had severe headaches when she was receiving intravenous immune globulin (IVIG), and did not have a response to rituximab. She comes for counseling because she would like to become pregnant. ITP is ...

SAN DIEGO, CA—Standard-dose rituximab plus multiple courses of pulse dexamethasone was shown to be active with manageable toxicity in patients with immune thrombocytopenia (ITP), according to ...

In the treatment of idiopathic thrombocytopenic purpura (ITP), the addition of rituximab (MabThera, Roche) to dexamethasone doubles the response rate, compared with dexamethasone alone ...

The combination of dexamethasone plus rituximab may be a safe and effective treatment option for patients with previously untreated idiopathic thrombocytopenic purpura, according to the results of ...

Adjuvant low-dose rituximab in combination with plasma exchange and steroids appeared effective for the treatment of acquired thrombotic thrombocytopenic purpura, according to results of a ...

To this end, Erkan and colleagues evaluated the safety and efficacy of rituximab in the treatment of several manifestations attributed to APS, including thrombocytopenia, cardiac valve disease ...

Inflammatory responses to cell-associated or tissue-associated immune complexes are key elements in the pathogenesis of several autoimmune diseases, including rheumatoid arthritis, systemic lupus ...

A 2022 study also indicates that race affects overall relapse risk and response to rituximab, a medication doctors may use off label to treat thrombocytopenia. The researchers suggest state that ...

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...

"While rituximab therapy for chronic ITP has been an exciting development, until now, due to a lack of sufficient patient numbers and follow-up in previous studies, we have only known how this ...